

### REMARKS

The claims in the application are 1-13. Entry of the amendment to the specification is respectfully requested.


Attention is respectfully directed to the specification which now contains an elaboration of certain inherent disclosure contained in parent application Ser. No. 09/302,620. More particularly, in the Background, at page 3, an explanation is provided that certain eukaryotes had recently (approximately after 1989) been determined not to adhere to the "universal" genetic code. This applies to certain of the species of yeast, e.g., *C. tropicalis*, discussed in the present application. According to the "universal" genetic code used by most living organisms, the codon CTG is translated as a leucine whereas according to the so-called "non-universal" code described, e.g., by Ueda et al., *Biochemie* (1994) 76, 1217-1222, CTG is translated as a serine.

This dichotomy impacts on the present disclosure since both *Candida* and *E. coli* were used in the Examples contained in the specification. Thus, e.g., in Example 3, transformed *E. coli* that express the cloned genes would have actually used the universal genetic code and expressed proteins containing a leucine where coded for by the CTG codon. Conversely, when expressed in *C. tropicalis*, see e.g., Examples 4 and 9, genes having the CTG codon would translate a serine where appropriate.

Nine of the genes described in the present specification contain at least one CTG codon, namely, *CYP52A1A*, *CYP52A3B*, *CYP52A5A*, *CYP52A5B*, *CYP52A8A*, *CYP52A8B*, *CYP52D4A*, *CPRA* and *CPRB*. Since the nucleic acid sequences were disclosed in the parent application in connection with each of these genes, and they were subject to expression in both "universal" code organisms and "non-universal" code organisms, the disclosure of two versions of each of the *CYP52A1A*, *CYP52A3B*, *CYP52A5A*, *CYP52A5B*, *CYP52A8A*, *CYP52A8B*, *CYP52D4A*, *CPRA* and *CPRB* proteins is inherent in the parent specification. Consequently, the explicit indication of "non-universal" code versions as set forth in SEQ ID NOS. 110 through 118 is not new matter. See also, the Summary of the Invention and the paragraph bridging pages 27 and 28 of the present specification.

Favorable consideration of the application as amended is respectfully requested. Early favorable action is earnestly solicited. If this is any point requiring discussion, the Examiner is respectfully requested to telephone the undersigned attorney for Applicants at the below-listed address.

Respectfully submitted,

  
Jeffrey S. Steen  
Attorney for Applicants  
Reg. No. 32,063

DILWORTH & BARRESE, LLP.  
333 Earle Ovington Boulevard  
Uniondale, New York 11553  
(516) 228-8484 (Telephone)  
(516) 228-8516 (Facsimile)

JSS:ml